Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.04 USD Market Closed
Market Cap: 10.6m USD

Wall Street
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

There are no price targets for ADAP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Adaptimmune Therapeutics PLC Competitors:
Price Targets
ALKS
Alkermes Plc
57% Upside
NIOX
Niox Group PLC
23% Upside
9966
Alphamab Oncology
2% Downside
397030
AprilBio Co Ltd
0% Downside
CRBU
Caribou Biosciences Inc
560% Upside
PASG
Passage Bio Inc
271% Upside
6855
Ascentage Pharma Group International
90% Upside
2142
Hbm Holdings Ltd
5% Upside

Revenue
Forecast

Revenue Estimate
Adaptimmune Therapeutics PLC

For the last 11 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 68%. The projected CAGR for the next 4 years is 9%.

68%
Past Growth
9%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ADAP's stock price target?
Not Available

ADAP doesn't have any price targets made by Wall Street professionals.

What is Adaptimmune Therapeutics PLC's Revenue forecast?
Projected CAGR
9%

For the last 11 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 68%. The projected CAGR for the next 4 years is 9%.

Back to Top